Yes December could be a good month. I would also pay close attention to trading on Dec 31 - if there's a lot of end-of-year (end-of-quarter) selling it could drop substantially and that would be a great buying opportunity, as it's almost certainly going to rise on Jan 4 (first trading day of the year) as institutional investors look to increase their positions for what is sure to be an active 2016.
Sunshine you're getting a little mixed up. I could see TROV's technology replacing blood-based tumor markers (it likely will) but if a patient has a chronic cough they're going to need imaging either way. Say someone comes into the office with lung cancer risk factors / symptoms and their urine assay for tumor markers is really high... you still need to do a CT scan to figure out where the cancer is to determine whether it's operable, amenable to radiation, etc. This kind of technology will never be (and should never be) first line testing for common conditions.
Huge unanswered question: why was an 'unplanned' interim analysis done? It is no small deal to look at data from a study. They really need to explain how exactly things happened. I got out at the open this morning. Looks like I wasn't the only one. Definitely smells fishy to me. And I have very little faith in the honesty of Israel's biotech culture after the Andromeda / Hyperion situation. You make your own choice. But I would HIGHLY recommend not just regurgitating press releases when supporting your point of view.
who says you're not allowed to publicly question? You had a previous post that was deleted - this happens all the time on these message boards for reasons I can't understand.
As an owner of this stock, I have to admit: this smells fishy. What was the reason for the interim analysis? It was "unplanned" so what prompted it? And why does the press release mention 25 patients and report results for just 12? No explanation for this. And not to impugn an entire country based on one company's actions, but the recent Hyperion / Andromeda fiasco is sitting in the background of all this for me, and I'd rather not be burned twice.
If your portfolio allocation is already at target there's no reason to keep buying. At the end of the day it's a speculative biotech. Blanket advice like that is not helpful. If you've already doubled down no reason to keep going as the losses build.
Here, watching patiently. I've been holding STML since $19 in early 2014. Still optimistic, but over a ~4-5 year timeline. They're likely about 2 years from any approval and the market is increasingly demanding of even late-stage biotechs these days. Unless a positive phase 2/3 trial readout or approval is imminent, they tend to just bounce around. Very bright future, but I doubt today's action will end up being much more than just noise on an already volatile chart.
Which results are we talking about here? Analysis of the primary endpoint of the sarcoma trial is targeted for Q1 2016 - see their press release from Nov 11 last year